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Abstract
Levels of the peptide hormone adrenomedullin (AM) are elevated during normal pregnancy, but
whether this differs during complications of pregnancy remains unresolved. AM can be quantified
by measuring its preprohormone byproduct, midregional pro-adrenomedullin (MR-proADM).
MR-pro ADM has shown prognostic value as a biomarker of heart failure, sepsis, and community-
acquired pneumonia. Given the relevance of AM to pregnancy, we tested the hypothesis that MR-
proADM provides a biomarker for preeclampsia. We find that MR-proADM plasma
concentrations are blunted in severe preeclampsia and that MR-proADM is similarly effective as
established biomarkers endoglin and placental growth factor at discriminating patients with severe
preeclampsia from controls.
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Introduction
Preeclampsia is a common pregnancy complication characterized by hypertension and
proteinuria [1]. Identification of novel serum biomarkers for this potentially dangerous
condition is highly desirable. The peptide hormone adrenomedullin (AM) has garnered
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attention as a candidate biomarker of preeclampsia because its levels are elevated during
pregnancy [2] but often altered in pregnancy complications [3]. Additionally,
polymorphisms in the ADM gene have been associated with preeclampsia [4].
Data from AM loss- and gain-of-function mouse models support a role for AM in
placentation. Remodeling of uterine spiral arteries, conduits of the uteroplacental circulation,
is critical for proper placentation [5] and is accomplished in part by crosstalk between
uterine natural killer (uNK) cells and trophoblast cells of the placenta [6]. Compared to wild
type placentas, Adm-/- placentas exhibit fewer uNK cells and insufficient spiral artery
remodeling [7]. Placentas from an animal model of AM overexpression (Admhi/hi) [8]
concordantly exhibit more uNK cells than wild type placentas and upregulate expression of
uNK cell-secreted signaling molecules [7]. Adm+/- intercrosses commonly produce embryos
demonstrating fetal growth restriction and morphological abnormalities, both common
consequences of placental disorders [9].
These data underscore the role of AM in placentation and its potential as a biomarker of
preeclampsia. Previous studies arrived at inconsistent conclusions about changes in AM
levels in preeclampsia [3], likely due to the brief half-life of AM [10] and its interaction with
a binding protein [11]. Recently, an assay was developed to detect midregional pro-
adrenomedullin (MR-proADM), a cleaved byproduct of the preprohormone that is in direct
correlation with AM [12]. Here, we measured MR-proADM plasma concentrations in
women with severe preeclampsia and compared this precursor peptide to previously
established biomarkers of preeclampsia.
Methods
Study design and patient samples
The study was approved by the Institutional Review Boards of Duke University and the
University of North Carolina at Chapel Hill. Thirty patients with preeclampsia and 30
patients without preeclampsia delivering at Duke University Hospital with available plasma
samples were selected from the Pregnancy Outcomes: Blood and Tissue Repository study,
which collected biological specimens from patients at the time of presentation and delivery.
We subsequently limited our experimental group to women with severe preeclampsia by
excluding women with mild preeclampsia (n=5). Additionally, women providing postpartum
plasma samples (n=12), women carrying twin pregnancies (n=3), and smokers (n=7) were
excluded from the original cohort. Former smokers were considered nonsmokers.
Immunoassays
Endoglin and placental growth factor (PlGF) plasma concentrations were measured using
commercial ELISA kits (R&D Systems, Minneapolis, MN) (Supplementary Table 1).
Plasma samples were diluted 1:5 for endoglin and 1:2 for PlGF. MR-proADM plasma
concentrations were measured undiluted by Phadia Immunology Reference Laboratory
(Portage, MI) using a commercial immunofluorescent assay (B·R·A·H·M·S KRYPTOR,
Hennigsdorf, Germany) (Supplementary Table 1).
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Student's t-tests were performed in GraphPad Prism 5.0. F tests were performed in R.
Logistic regression and ROC analysis were performed using R package glm with no cross
validation. P values < 0.05 were considered statistically significant.
Results
Table 1 summarizes the clinical characteristics of the patients whose plasma was analyzed in
this study (Figure 1A). Plasma samples from controls and from women with severe
preeclampsia were analyzed by ELISA for conventional biomarkers of preeclampsia. As
expected [13], soluble endoglin plasma concentrations were elevated in women with severe
preeclampsia (Figure 1B), and placental growth factor (PlGF) plasma concentrations were
blunted in women with severe preeclampsia (Figure 1C). After confirming that plasma from
women with severe preeclampsia adhered to conventional biomarker paradigms, plasma
samples were then analyzed by a sandwich immunoassay for MR-proADM. In women with
severe preeclampsia, MR-proADM concentrations were blunted (Figure 1D). While plasma
freezer storage time differed significantly between groups, storage time did not correlate
with MR-proADM concentration (r2=0.004, data not shown).
To compare endoglin, PlGF, and MR-proADM as biomarkers of severe preeclampsia, we
generated logistic regression models for each of these biomarkers alone and in combination.
We then analyzed these models by generating receiver operating characteristic (ROC)
curves and comparing their respective areas under the curve (AUC) (Figure 2). Based on
AUCs, we concluded that, in this dataset, endoglin (AUC=0.73) and MR-proADM
(AUC=0.69) classified patients similarly, while PlGF is slightly more informative
(AUC=0.85). In multiple logistic regression, endoglin and MR-proADM together are better
discriminators than either alone (AUC=0.80), as are PlGF and MR-proADM together
(AUC=0.87).
Discussion
As predicted by the Adm-deficient mouse model [7, 9, 14], we found blunted MR-proADM
plasma concentrations in women with severe preeclampsia. Interestingly, during our
revision process, Wellmann et al. reported elevated MR-proADM in preeclampsia using a
similarly sized cohort [15]. However, their study did not distinguish between mild and
severe preeclampsia and included two key groups of patients that we excluded from our
study: patients carrying multiple pregnancies and smokers. Both twins and smoking have
been shown to upregulate Adm expression, which could explain the finding of elevated AM
plasma concentrations in their patients [16-18].
Moreover, we found that MR-proADM is similarly effective as endoglin and PlGF at
discriminating between patients with severe preeclampsia and controls. However, as
acknowledged as a methodology limitation in both studies, the disease prevalence is higher
in the study population than in the general population. Additionally, both studies collected
plasma samples late in pregnancy, while an ideal biomarker would detect preeclampsia early
in pregnancy before the clinical disease becomes apparent. Ultimately, the data presented
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here warrant further investigation of MR-proADM at earlier gestational ages with the
ultimate goal of predicting which women will develop preeclampsia later in pregnancy.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• MR-proADM is a predictive and prognostic biomarker of heart failure and
pneumonia.
• Animal models have defined a critical role for adrenomedullin in placentation.
• We conclude that MR-proADM is a novel plasma biomarker for severe
preeclampsia.
• MR-proADM is similarly effective as endoglin at classifying patients from
controls.
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(A) Patients excluded from the original 60 patient cohort and (B-D) plasma concentrations
of (B) endoglin, (C) placental growth factor (PlGF), and (D) MR-proADM measured by
ELISA (A, B) or sandwich immunoassay (C) in controls and women with severe
preeclampsia (PE). Boxes extend from the 25th to the 75th percentile. Whiskers extend 1.5
times the interquartile range below and above the 25th and 75th percentiles, respectively.
Horizontal lines dividing the boxes identify the median of each group. Significant outliers,
determined by Grubbs' test, are identified by a solid black dot and excluded from the
analysis in this figure. Four plasma samples were too concentrated to be detected within the
range of the endoglin ELISA standard curve; one of these samples belonged to the control
group, while the other three belonged to the PE group. Likewise, four plasma samples were
too dilute to be detected within the range of the PlGF ELISA standard curve; all four of
these samples belonged to the PE group. These too-concentrated or too-dilute samples were
excluded from analysis. Groups were compared by Student's t-test. *p=0.046 (A) and 0.007
(B), and 0.041 (C). PP, postpartum.
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ROC curves for five logistic regression models of current severe preeclampsia based on
biomarker concentrations. Plus signs separate covariates. Samples that fell above (endoglin,
n=4) or below (PlGF, n=5) the ELISA standard curve were equated with the upper and
lower bounds, respectively, of the standard curve. ENG, endoglin.
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Table 1
Clinical characteristics of study patients.
Control (n=18) Severe Preeclampsia (n=15) p valueb
Age (years) 33.8 ± 4.5 (25-41) 28.5 ± 6.6 (21-41) 0.01
BMI at delivery 31.4 ± 6.7 (23.2-48.6) (n=17) 38.2 ± 9.2 (25.6-54.0) 0.03
Gravidity 3 (3-4) 2 (1-3) 0.02
Parity 1 (1-2) 0 (0-2) 0.14
Ethnicity
 White 12 7
 Black 3 8 0.99
 Asian 3 0 0.07
Gestational age at delivery (weeks) 38.7 ± 0.8 (37.2-39.7) 33.9 ± 4.2 (27.4-39.9) <0.001
Labor status
 Not in labor 14 10
 In labor 4 5 0.48
Mode of delivery
 Cesarean 16 12
 Vaginal 2 3 0.48
Blood pressure
 Systolic (mm Hg) 115.9 ± 13.1 (110-148) 164.7 ± 13.8 (143-186) <0.001
 Diastolic (mm Hg) 72.5 ± 9.1 (57-92) 103.9 ± 8.4 (90-115) <0.001
Proteinuria
 Protein dip 0.28 ± 0.75 (0-3) 2.6 ± 1.1 (1-4) (n=10) <0.001
Past medical history
 Hypertension 0 7
Pregnancy-related morbidity
 Gestational diabetes 1 4 0.12
 HELLP syndrome 0 3
 Chorioamnionitis 0 1
Birthweight (grams) 3488 ± 393 (2980-4710) 2309 ± 1191 (590-4850) <0.001
Fetal growth restriction 0 3
Freezer storage time (days) 426.1 ± 295.8 (133-1024) 837.2 ± 322.0 (155-1099) <0.001
Data are presented as mean ± standard deviation (range). Gravidity and parity are presented as median (interquartile range). The n is provided if
different from the group n due to unavailable data.
BMI, body mass index; HELLP, hemolysis, elevated liver enzymes, low platelets.
a
Standard diagnostic criteria for severe preeclampsia were used: a systolic blood pressure ≥160 mm Hg and/or a diastolic blood pressure ≥110 mm
Hg and proteinuria >500 mg/24 hours.
b
Student's t-test for continuous variables, F test for categorical variables.
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Table 2
Plasma concentrations of endoglin, PlGF, and MR-proADM in controls and women with severe preeclampsia.
Control PE p valuea
Endoglin (ng/mL) 16.5 ± 9.6 (2.2-32.0) (n=17) 25.3 ± 13.1 (4.2-46.4) (n=12) 0.046
PlGF (pg/mL) 317.3 ± 211.7 (15.1-784.4) 113.4 ± 120.1 (5.9-406.4) (n=11) 0.007
MR-proADM (nmol/L) 1.6 ± 0.6 (0.8-2.9) 1.2 ± 0.5 (0.3-2.0) 0.041
Data are presented as mean ± standard deviation (range). Plasma samples that were too concentrated or too dilute to be detected within the range of
the ELISA standard curve for endoglin and PlGF, respectively, were excluded from analysis. Grubbs' test detected one significant outlier in the
PlGF concentrations in the PE group; this outlier was also excluded from analysis.
a
Student's t-test.
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